Dar Al Dawa Development & Investment operates in the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Dar Al Dawa Development & Investment with three other
pharmaceutical manufacturers in Middle East:
Glaxo Smith Kline
sales of 1.17 billion Egyptian Pounds [US$64.94 million]
of which 93%
was Medical Sector),
(182.39 million Israel Shekels [US$51.10 million]
of which 104%
was Nutrition), and
Egypt International Pharmaceuticals
based in Egypt
(1.97 billion Egyptian Pounds [US$109.70 million]
of which 100%
Dar Al Dawa Development & Investment reported sales of 60.88 million Jordanian Dinars (US$85.62 million)
December of 2016.
decrease of 2.0%
versus 2015, when the company's sales were 62.14 million Jordanian Dinars.
Contributing to the drop in overall sales was the 9.6% decline
in Infant Food and Milk, from 13.56 million Jordanian Dinars to 12.26 million Jordanian Dinars.
However, these declines were partially offset by the increase in sales of
Pharmaceuticals (up 0.1% to 48.61 million Jordanian Dinars)